MEAN IOP CHANGE IN NON-GLAUCOMATOUS PATIENTS WITH MACULAR EDEMA SUBSEQUENTLY INTRAVITREAL INJECTION AVASTIN
Keywords:macular edema, intravitreal Avastin, intraocular pressure.
AbstractBackground: The accumulation of fluid between the retinal layers is called retinal or macular oedema, while intraretinal oedema, or macular oedema, and refers to fluid accumulation directly within the retinal. Purpose of the study was to evaluate the effects of intravitreal injections of bevacizumab on intraocular pressure (IOP) in Non-Glaucomatous patients with Macular Oedema. Methods: A pre-and post-interventional study was conducted. 220 patients were studied utilizing a non-probability, consecutive sampling method. Open Epi software was used to determine the sample size. The department of ophthalmology at Islamabad's Tertiary Care Hospital hosted the study, which lasted six months. Results: The study's participants ranged in age from 30 to 60, with a mean age of 50.38±6.53 years. Male to female ratio of these 220 patients was 1:1.6, with 86 (39.09%) men and 134 (60.91%) women. The mean IOP at baseline was 11.57±1.42 mmHg, and the mean IOP one month after the injection was 12.81±1.18 mmHg, with a mean change in IOP of 1.24±0.87 mmHg. Conclusion: This study found that non-glaucomatous patients with macular oedema experienced a high mean change in intraocular pressure (IOP) after intravitreal Avastin.
Tah V, Orlans HO, Hyer J. Anti-VEGF therapy and the retina: an update. J Ophthalmol. 2015;2015:627-4.
Ricca AM, Morshedi RG, Wirostko BM. High intraocular pressure following anti-vascular endothelial growth factor therapy: proposed pathophysiology due to altered nitric oxide metabolism. J Ocul Pharmacol Ther. 2015;31:2-10.
Li X, Zarbin MA, Bhagat N. Anti-vascular endothelial growth factor injections: the new standard of care in proliferative diabetic retinopathy. Dev Ophthalmol. 2017;60:131–42.
Atchison EA, Wood KM, Mattox CG, et al. The real-world effect of intravitreous anti-vascular endothelial growth factor drugs on intraocular pressure: an analysis using the IRIS registry. Ophthalmol. 2018;125:676-82.
Hoguet A, Chen PP, Junk AK, Mruthyunjaya P, Nouri-Mahdavi K, Radhakrishnan S, et al. The effect of anti-vascular endothelial growth factor agents on intraocular pressure and glaucoma. Ophthalmol. 2019;126:611-22.
Maria DA, Alina PC, Matei PC, Adriana N, Dragos S. “Off-label” use of intravitreal bevacizumab in non-ischemic macular edema secondary to retinal vein obstructions. Romanian J Ophthalmol. 2016;60(2):90-5.
Moraru A, Pînzaru G, Moţoc A, Costin D, Brănişteanu D. Incidence of ocular hypertension after intravitreal injection of anti-VEGF agents in the treatment of neovascular AMD. Rom J Ophthalmol. 2017;61(3):207–11.
Hollands H, Wong J, Bruen R, Campbell RJ, Sharma S, Gale J. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol /Journal Canadien d' Ophtalmologie 2007; 42(6): 807-11.
Lemos-Reis R, Moreira-Gonçalves N, Melo AB, Carneiro ÂM, Falcão-Reis FM. Immediate effect of intravitreal injection of bevacizumab on intraocular pressure. Clinical ophthalmology (Auckland, NZ) 2014; 8: 1383.
Kiddee W, Montriwet M. Intraocular pressure changes in non-glaucomatous patients receiving intravitreal anti-vascular endothelial growth factor agents. PLoS One. 2015;10(9):e0137833.
Lee JW, Park H, Choi JH, Lee HJ, Moon SW, Kang JH, et al. Short-term changes of intraocular pressure and ocular perfusion pressure after intravitreal injection of bevacizumab or ranibizumab. BMC ophthalmology 2016; 16(1): 1.
Mansoori T, Agraharam SG, Manwani S, Balakrishna N. Intraocular Pressure Changes after Intravitreal Bevacizumab or Ranibizumab Injection: A Retrospective Study. J Curr Ophthalmol. 2021 Mar 26;33(1):6-11. doi: 10.4103/JOCO.JOCO_5_20. PMID: 34084950; PMCID: PMC8102956.
Kim JE, Mantravadi AV, Hur EY, Covert DJ. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol. 2008;146:930–40. [PubMed] [Google Scholar]
Kiddee W, Montriwet M (2015) Intraocular Pressure Changes in Non-Glaucomatous Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Agents. PLoS ONE 10(9): e0137833. https://doi.org/10.1371/journal.pone.0137833
Bakri SJ, McCannel CA, Edwards AO, Moshfeghi DM. Persistent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol 2008;246:955–958. pmid:18425523
Adelman RA, Zheng Q, Mayer HR. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J Ocul Pharmacol Ther 2010;26:105–110. pmid:20187807
Rosenfeld PJ, Heier JS, Hantsbarger G, Shams N. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:623–32
Bakri SJ, Pulido JS, McCannel CA, Hodge DO, Diehl N, Hillemeier J. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye (Lond). 2007;23:181–5.
Rasier R, Artunay O, Yuzbasioglu E, Sengul A, Bahcecioglu H. The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension. Eye (Lond). 2009;23:1714–8.
Baek SU, Park IW, Suh W. Long-term intraocular pressure changes after intravitreal injection of bevacizumab. Cutan Ocul Toxicol. 2016 Dec;35(4):310-4. doi: 10.3109/15569527.2015.1124886. Epub 2016 Jan 28. PMID: 26820610.
Nariani A, Williams B, Hariprasad SM. Long –term effect of anti-vascular endothelial growth factor injections on intraocular pressure. Indian Journal of Ophthalmology. 2016 Sep, 64 (9): 643-647.
Kamath YS, Rander A, Shailaja BS, Rao LG, Bhandary SV. The intraocular pressure changes following intravitrealbevacizumab injections in an Indian population. DOI: 10.18231/2395-1451.2018.0020.
Lee JW, Park H, Choi JH, Lee HJ, Moon SW, Kang JH, et al. Short-term changes of intraocular pressure and ocular perfusion pressure after intravitreal injection of bevacizumab or ranibizumab. BMC Ophthalmol. 2016; 16: 69.
Jaffar S, Tayyab A, Matin ZI, Masrur A, Naqaish R. Effect of intra vitreal injection of bevacizumab on intra-ocular pressure. J Ayub Med Coll Abbottabad 2016; 28 (2): 360–3.
Cubuk MO, Erkan U. Intraocular Pressure Changes in Eyes Treated with Intravitreal Injections of Anti-Vascular Endothelial Growth Factor for Age Related Macular Degeneration: The Results of Real Worlds. RetinaVitreus/Journal of Retina-Vitreous. 2019;28:165-170.
Copyright (c) 2023 Adila Anwar, Ayyaz Hussain Awan, Anjum Imdad, Sufian Ali Khan, Mutahir Shah, Misbah Naeem
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.